Symbols

LUNG

Pulmonx·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LUNG

Pulmonx Corporation

A global leader in minimally invasive treatments for severe lung disease

Industry

Healthcare Equipment and Supplies

Established Date

12/26/1995

Listing Date

10/01/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

296

Fiscal Year Ends

12-31

Website

www.pulmonx.com

Security Type

Common stock

Office address

700 Chesapeake Drive, Redwood City, California 94063

Business

Introduction

Pulmonx Corporation was incorporated in California as Pulmonx on December 26, 1995 and re-incorporated in Delaware on December 4, 2013. The company is a commercial-stage medical technology company that provides minimally invasive treatment for patients with severe emphysema, a chronic obstructive pulmonary disease. The company's solutions, consisting of the Zephyr Endobronchial Valve, the Chartis Lung Assessment System and the LungTraX platform, are designed to treat a large number of patients whose medical management has reached the limit, does not want or is not eligible for surgery. The company has subsidiaries in Germany, Switzerland, Australia, the United Kingdom, Italy, France, Hong Kong and Japan.

Company Financials

EPS

LUNG has released its 2025 Q4 earnings. EPS was reported at -0.25, versus the expected -0.39, beating expectations. The chart below visualizes how LUNG has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LUNG has released its 2025 Q4 earnings report, with revenue of 22.60M, reflecting a YoY change of -4.91%, and net profit of -10.43M, showing a YoY change of 20.87%. The Sankey diagram below clearly presents LUNG's revenue sources and cost distribution.